Physician profile
Jenna Lorusso
NPI 1942840913
$1,165.68
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,050 · 2022: $116.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $285.31 | 2021-2022 | |
| Novo Nordisk INC | $143.07 | 2021 | |
| Glaxosmithkline, LLC. | $85.65 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $82.64 | 2021 | |
| Lilly USA, LLC | $73.98 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.63 | 2021 | |
| Astellas Pharma US INC | $72.04 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $68.30 | 2021 | |
| Amarin Pharma, INC. | $44.88 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $39.15 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $33.98 | 2021 | |
| Pfizer INC. | $33.84 | 2021 | |
| Daiichi Sankyo INC. | $33.49 | 2021 | |
| Merck Sharp & Dohme LLC | $28.94 | 2021 | |
| Nevro Corp. | $19.57 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $17.67 | 2021 | |
| Janssen Pharmaceuticals, INC | $15.39 | 2021 | |
| Esperion Therapeutics, INC. | $15.15 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenna Lorusso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.